Darkest Hour for U.S. Biotech Stocks! Top FDA Vaccine Official Resigns, Wall Street Slams HHS Secretary RFK Jr.

Source Tradingkey

TradingKey - With the appointment of vaccine skeptic Robert F. Kennedy Jr. (RFK Jr.) as U.S. Secretary of Health and Human Services, coupled with the forced resignation of Peter Marks, a key figure at the U.S. Food and Drug Administration (FDA), is casting a long shadow over the U.S. pharmaceutical regulatory environment. The resulting uncertainty has triggered sharp declines in vaccine stocks and broader healthcare equities.

On Monday (March 31), U.S. biopharmaceutical stocks plunged across the board. The SPDR S&P Biotech ETF (XBI) fell as much as 6% during intraday trading before closing down 3.91%, bringing its year-to-date loss to approximately 10%.

Vaccine makers were particularly hard hit: Moderna dropped 8.90%, while Novavax fell 8.43%. Gene therapy firms also suffered steep losses, with Taysha Gene Therapies (TSHA.US) plunging 27.98%, Solid Biosciences (SLDB) declining 14.35%, and Sarepta Therapeutics down 9.36%.

In Europe, shares of weight-loss drug giant Novo Nordisk fell 27% in March, marking their worst monthly performance since June 2022 and the largest monthly drop since the dot-com bubble. Its U.S.-listed shares (NVO.US) are down approximately 18% year-to-date.

Since Donald Trump returned to the White House, the U.S. pharmaceutical sector has come under sustained pressure, driven largely by the controversial appointment of RFK Jr., a prominent anti-vaccine advocate, as health secretary. RFK Jr. has frequently questioned the safety and efficacy of vaccines.

The situation escalated when Dr. Peter Marks, a senior FDA official widely regarded as one of the most influential figures in modern vaccine regulation, was forced to resign following policy clashes with RFK Jr. Marks played a central role in accelerating vaccine development during Trump’s first term.  According to sources familiar with the matter, Marks wrote in his resignation letter: "Truth and transparency are no longer needed here."

A former FDA advisor described Marks’ removal during RFK Jr.'s sweeping restructuring plans as a high-risk move that could delay approval timelines, create oversight confusion, and lead to inconsistent regulatory enforcement.

RFK Jr. has recently announced plans to consolidate the Department of Health and Human Services, reducing its 28 divisions to 15  and cutting the workforce from 82,000 to 62,000 full-time employees.

Analysts at Cantor Fitzgerald bluntly criticized RFK Jr.'s leadership, warning that his "apparent anti-science and libertarian agenda" poses a significant threat to public health. Media outlets noted that it is highly unusual for Wall Street analysts to directly target high-ranking government officials in such terms.

Stifel analysts called Marks' resignation “the biotech sector’s worst-case scenario under the Trump administration. BMO analysts added that the y sector was already under immense pressure from broader macroeconomic concerns, and Marks'  exit further erodes investor confidence. 

Truist analysts forecast heightened volatility in the coming days for vaccine-related companies as investors assess the regulatory uncertainty following Marks’ departure.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Ripple (XRP) Price Sees a Surge, Solana Targets $600 in 2025 as Investors Increase Focus on New AltcoinThe cryptocurrency market is showing renewed momentum as Ripple (XRP) experiences a significant price surge, and Solana (SOL) sets its sights on a bold $600 target by 2025. Meanwhile, a rising altcoin, Lightchain AI, is capturing investor attention with its innovative ecosystem and strong presale performance, making it a compelling choice for forward-looking investors. Ripple […]
Author  Cryptopolitan
Jan 15, Wed
The cryptocurrency market is showing renewed momentum as Ripple (XRP) experiences a significant price surge, and Solana (SOL) sets its sights on a bold $600 target by 2025. Meanwhile, a rising altcoin, Lightchain AI, is capturing investor attention with its innovative ecosystem and strong presale performance, making it a compelling choice for forward-looking investors. Ripple […]
placeholder
What Crypto Whales are Buying For May 2025Crypto whales are making bold moves heading into May 2025, and three tokens are standing out: Ethereum (ETH), Artificial Superintelligence Alliance (FET), and Onyxcoin (XCN).
Author  Beincrypto
Apr 21, Mon
Crypto whales are making bold moves heading into May 2025, and three tokens are standing out: Ethereum (ETH), Artificial Superintelligence Alliance (FET), and Onyxcoin (XCN).
placeholder
Ethereum Price Ready to Surge—$2,000 Level Could Be Within ReachEthereum price started a fresh increase above the $1,800 zone. ETH is now rising and attempting a move above the $1,850 resistance. Ethereum started a fresh recovery wave above the $1,820 resistance.
Author  NewsBTC
May 08, Thu
Ethereum price started a fresh increase above the $1,800 zone. ETH is now rising and attempting a move above the $1,850 resistance. Ethereum started a fresh recovery wave above the $1,820 resistance.
placeholder
Ethereum Price Explodes Past $2,200 with 25% Surge—Momentum Builds FastEthereum price started a fresh surge above the $2,000 zone. ETH is now up over 25% and consolidating gains near the $2,200 zone. Ethereum started a fresh surge above the $2,000 resistance.
Author  NewsBTC
May 09, Fri
Ethereum price started a fresh surge above the $2,000 zone. ETH is now up over 25% and consolidating gains near the $2,200 zone. Ethereum started a fresh surge above the $2,000 resistance.
placeholder
Gold Price Forecast: XAU/USD holds above $3,300 on economic uncertainty, geopolitical risksThe Gold price (XAU/USD) rebounds to around $3,310 during the early Asian trading hours on Monday. Ongoing tariff uncertainty and persistent geopolitical tensions boost demand for safe-haven assets like gold.
Author  FXStreet
Yesterday 01: 23
The Gold price (XAU/USD) rebounds to around $3,310 during the early Asian trading hours on Monday. Ongoing tariff uncertainty and persistent geopolitical tensions boost demand for safe-haven assets like gold.
goTop
quote